Market Trends of Global Low Molecular Weight Heparin Industry
The Deep Vein Thrombosis Segment is Expected to Witness Significant Growth During the Forecast Period
Deep vein thrombosis (DVT), also known as venous thrombosis, occurs when a thrombus (blood clot) forms in veins deep within the body due to injury to the veins or sluggish blood flow. Blood clots can fully or partially stop blood flow through a vein. DVTs are commonly found in the lower leg, thigh, or pelvis but can also occur in the arm, brain, intestines, liver, or kidney.
The increasing prevalence of DVT is one of the major factors driving the segment's growth. For instance, in September 2023, according to the study published in Frontiers in Medicine, the prevalence of DVT was 7.6% in patients with liver cirrhosis. Additionally, in May 2023, another study published in Frontiers in Cardiovascular Medicine reported that the incidence of DVT was 9.3% among patients with acute and chronic spinal cord injury.
As LMWHs are more effective than no prophylaxis in preventing DVT and pulmonary thromboembolism in high-risk general surgical patients, the demand for LMWH in patients suffering from DVT is anticipated to increase over the coming years, driving the segment’s growth. Hence, owing to the above factors, the adoption of these products will likely increase among the target population, driving the segment’s growth.
North America is Expected to Dominate the Low Molecular Weight Heparin Market
North America is expected to dominate the market due to the growing burden of diseases, the rising geriatric population, and the rising number of product approvals. For instance, the statistics published by the United Health Foundation highlighted that there were more than 58 million individuals aged 65 and above in the United States, representing 17.3% of the nation's population, in 2022; the figure is estimated to reach 73.1 million, or 22%, by 2040. As the risk of venous thromboembolism is strongly associated with age, the demand for LMWH will also likely increase.
In January 2024, the data update by the National Center for Biotechnology Information showed that up to 200,000 people in the United States were affected with deep venous thrombosis. Among those, 50,000 cases resulted in pulmonary embolism. Deep venous thrombosis (DVT), which leads to pulmonary embolism (PE), is the third most common cardiovascular disease after myocardial infarction and stroke. Such an increase in the target population will ultimately boost the adoption of LMWH products, positively impacting market growth.
Therefore, factors such as the growing burden of the geriatric population and the high prevalence of blood disorders are expected to contribute to market growth.
